Subtype Is a Predictive Factor of Nonsentinel Lymph Node Involvement in Sentinel Node-Positive Breast Cancer Patients

다국어 초록 (Multilingual Abstract)

Purpose: This study aimed to identify the effect of breast cancersubtype on nonsentinel lymph node (NSLN) metastasis in patientswith a positive sentinel lymph node (SLN). Methods: Therecords of 104 early breast cancer patients with a positive SLNbetween April 2009 and September 2013 were retrospectivelyevaluated. All patients underwent axillary lymph node dissection.
The effects of the tumor subtype (luminal A, luminal/HER2+, humanepidermal growth factor receptor 2 [HER2] overexpression,and triple-negative) and other clinicopathological factors onNSLN metastasis were examined by univariate and multivariatestatistical analyses. Results: Fifty of 104 patients (48%) exhibitedNSLN metastasis. Univariate and multivariate analyses revealedthat tumor size and the ratio of positive SLNs were significantrisk factors of NSLN metastasis in patients with a positive SLN.
The rate of NSLN metastasis was higher in patients with luminal/HER2+ and HER2 overexpression subtypes than that in patientswith other subtypes in the univariate analysis (p<0.001). In themultivariate analysis, both patients with luminal/HER2+(p<0.006) and patients with HER2 overexpression (p<0.031)subtypes had a higher risk of NSLN metastasis than patientswith the luminal A subtype. Conclusion: Subtype classificationshould be considered as an independent factor when evaluatingthe risk of NSLN metastasis in patients with a positive SLN. Thisresult supports the development of new nomograms includingbreast cancer subtype to increase predictive accuracy.

참고문헌 (Reference)

1 Carey LA, "The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes" 13 : 2329-2334, 2007

2 Reyal F, "The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma" 6 : e20297-, 2011

3 Veronesi U, "Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes" 349 : 1864-1867, 1997

4 Reynolds C, "Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer?" 17 : 1720-1726, 1999

5 Gabos Z, "Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer" 24 : 5658-5663, 2006

6 Rahusen FD, "Predictive factors for metastatic involvement of nonsentinel nodes in patients with breast cancer" 136 : 1059-1063, 2001

7 Nos C, "Prediction of tumour involvement in remaining axillary lymph nodes when the sentinel node in a woman with breast cancer contains metastases" 90 : 1354-1360, 2003

8 Schrenk P, "Prediction of non-sentinel lymph node status in breast cancer with a micrometastatic sentinel node" 92 : 707-713, 2005

9 Degnim AC, "Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram" 190 : 543-550, 2005

10 Reyal F, "Non-sentinel lymph node metastasis prediction in breast cancer with metastatic sentinel lymph node: impact of molecular subtypes classification" 7 : e47390-, 2012

11 Kohrt HE, "New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients" 8 : 66-, 2008

12 Zhou W, "Molecular subtype classification is a determinant of non-sentinel lymph node metastasis in breast cancer patients with positive sentinel lymph nodes" 7 : e35881-, 2012

13 Perou CM, "Molecular portraits of human breast tumours" 406 : 747-752, 2000

14 Zhou WB, "Meta-analysis of sentinel lymph node biopsy at the time of prophylactic mastectomy of the breast" 54 : 300-306, 2011

15 Cheang MC, "Ki67Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer" 101 : 736-750, 2009

16 Sørlie T, "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications" 98 : 10869-10874, 2001

17 Chu KU, "Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection?" 229 : 536-541, 1999

18 Moghaddam Y, "Comparison of three mathematical models for predicting the risk of additional axillary nodal metastases after positive sentinel lymph node biopsy in early breast cancer" 97 : 1646-1652, 2010

19 Yin WJ, "Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients" 115 : 325-333, 2009

20 Hwang RF, "Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer" 10 : 248-254, 2003

21 Keshtgar MR, "Clinical role of sentinel-lymph-node biopsy in breast cancer" 3 : 105-110, 2002

22 Weigelt B, "Breast cancer molecular profiling with single sample predictors: a retrospective analysis" 11 : 339-349, 2010

23 Cheang MC, "Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype" 14 : 1368-1376, 2008

24 Cserni G, "Axillary sentinel node and tumour-related factors associated with non-sentinel node involvement in breast cancer" 34 : 519-524, 2004

25 Wolff AC, "American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer" 25 : 118-145, 2007

26 Hammond ME, "American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer" 28 : 2784-2795, 2010

27 Lyman GH, "American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer" 23 : 7703-7720, 2005

28 Veronesi U, "A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer" 349 : 546-553, 2003

29 Van Zee KJ, "A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy" 10 : 1140-1151, 2003

30 Pal A, "A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive" 95 : 302-309, 2008